Patents by Inventor Huayong Zhou

Huayong Zhou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof
    Patent number: 10472349
    Abstract: A mesylate salt of the compound of formula (I), the preparation method thereof, a pharmaceutical composition containing said salt and the use of said salt in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancers, in mammal, in particular human. The mesylate salt of the compound of formula (I) has a high bioavailability in animal, and can remarkably inhibit the growth of transplanted tumors in animal and show a good safety.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: November 12, 2019
    Assignee: SHANGHAI ALLIST PHARMACEUTICAL AND MEDICAL TECH CO
    Inventors: Huibing Luo, Huayong Zhou
  • SALT OF PYRIDINYL AMINO PYRIMIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
    Publication number: 20190100509
    Abstract: A mesylate salt of the compound of formula (I), the preparation method thereof, a pharmaceutical composition containing said salt and the use of said salt in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancers, in mammal, in particular human. The mesylate salt of the compound of formula (I) has a high bioavailability in animal, and can remarkably inhibit the growth of transplanted tumors in animal and show a good safety.
    Type: Application
    Filed: March 1, 2017
    Publication date: April 4, 2019
    Inventors: Huibing LUO, Huayong ZHOU
  • Pyridinylaminopyrimidine derivatives, preparation process and use thereof
    Patent number: 10072002
    Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: September 11, 2018
    Assignee: Shanghai Allist Pharmaceuticals, Inc.
    Inventors: Huibing Luo, Huayong Zhou, Shuhui Wang, Yong Wu
  • PYRIDINYLAMINOPYRIMIDINE DERIVATIVES, PREPARATION PROCESS AND USE THEREOF
    Publication number: 20170210739
    Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.
    Type: Application
    Filed: July 29, 2015
    Publication date: July 27, 2017
    Inventors: Huibing Luo, Huayong Zhou, Shuhui Wang, Yong Wu
  • Pyridinylaminopyrimidine derivatives, preparation process and use thereof
    Patent number: RE48687
    Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 17, 2021
    Assignee: Shanghai Allist Pharmaceuticals Co., Ltd.
    Inventors: Huibing Luo, Huayong Zhou, Shuhui Wang, Yong Wu
  • Pyridinylaminopyrimidine derivatives, preparation process and use thereof
    Patent number: RE49851
    Abstract: The present invention relates to pyridinylaminopyrimidine derivatives represented by the following formula (I), and pharmaceutically acceptable salts, preparation process and use thereof, wherein R1, R2, R3, R4, R5, m and A are defined as in the description. Pyridinylaminopyrimidine derivatives of the present invention can selectively inhibit the activity of mutant-type epidermal growth factor receptor (EGFR), have a good inhibition for the cancer cell proliferation, and therefore can be used as a therapeutic agent for treating tumors and relevant diseases.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: February 27, 2024
    Assignee: Shanghai Allist Pharmaceuticals Co., Ltd.
    Inventors: Huibing Luo, Huayong Zhou, Shuhui Wang, Yong Wu